Edwards Lifesciences (NYSE:EW) Given New $87.00 Price Target at Robert W. Baird

Key Points

• Robert W. Baird raised its price target on Edwards Lifesciences to $87 (from $85) while maintaining a "neutral" rating, implying roughly a 9.17% upside from the prior close.
• Edwards beat Q1 estimates with revenue of $1.65B (up ~16.7% YoY) and EPS of $0.78, and set FY2026 guidance of $2.95–$3.05 and Q2 guidance of $0.70–$0.76.
• Analysts remain constructive (consensus "Moderate Buy" and average target ~$95.48), but recent sizable insider selling and a post-earnings reversal raise the risk of near-term selling pressure despite heavy institutional ownership (~79.5%).

Edwards Lifesciences (NYSE:EW - Get Free Report) had its target price increased by equities researchers at Robert W. Baird from $85.00 to $87.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a "neutral" rating on the medical research company's stock. Robert W. Baird's price target would suggest a potential upside of 9.17% from the company's previous close.

EW has been the topic of a number of other research reports. Mizuho set a $95.00 price target on Edwards Lifesciences and gave the company an "outperform" rating in a report on Monday, April 13th. UBS Group restated a "neutral" rating and set a $94.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Piper Sandler restated an "overweight" rating and set a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Wells Fargo & Company boosted their price target on Edwards Lifesciences from $96.00 to $100.00 and gave the company an "overweight" rating in a report on Wednesday, February 11th. Finally, The Goldman Sachs Group restated a "buy" rating and set a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $95.48.

Edwards Lifesciences Stock Down 2.3%

Shares of NYSE:EW opened at $79.69 on Friday. Edwards Lifesciences has a 1 year low of $72.30 and a 1 year high of $87.89. The company has a market cap of $45.95 billion, a PE ratio of 43.55, a P/E/G ratio of 2.12 and a beta of 0.95. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. The stock's 50-day moving average is $81.54 and its 200 day moving average is $82.15.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The company had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. During the same quarter in the previous year, the business earned $0.64 EPS. Edwards Lifesciences's revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Sell-side analysts anticipate that Edwards Lifesciences will post 2.96 EPS for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 24,000 shares of the company's stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the transaction, the vice president owned 21,266 shares in the company, valued at approximately $1,782,941.44. This represents a 53.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the company's stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $80.98, for a total value of $82,518.62. Following the transaction, the vice president owned 33,934 shares in the company, valued at $2,747,975.32. This trade represents a 2.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 86,058 shares of company stock worth $7,118,636. Company insiders own 0.31% of the company's stock.

Institutional Trading of Edwards Lifesciences

Several hedge funds and other institutional investors have recently made changes to their positions in EW. Norges Bank purchased a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Edwards Lifesciences by 278.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company's stock worth $434,318,000 after buying an additional 4,108,270 shares during the last quarter. Viking Global Investors LP purchased a new stake in shares of Edwards Lifesciences in the 3rd quarter worth approximately $238,688,000. Marshall Wace LLP grew its stake in shares of Edwards Lifesciences by 66.1% in the 4th quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company's stock worth $505,160,000 after buying an additional 2,359,128 shares during the last quarter. Finally, Jennison Associates LLC grew its stake in shares of Edwards Lifesciences by 19.6% in the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company's stock worth $1,085,574,000 after buying an additional 2,287,783 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Key Headlines Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Q1 top-line beat and strong surgical product demand—Revenue rose ~16.7% YoY to about $1.65B, led by robust demand for artificial/transcatheter heart valves, which analysts flagged as the quarter’s standout driver. Read More.
• Positive Sentiment: Profitability and cash flow improvement—The company reported better-than-expected quarterly EPS per several outlets and showed improved operating profit and operating cash flow, supporting margins and longer-term earnings power. Read More.
• Neutral Sentiment: Guidance mostly in line but with range risk—Q2 EPS guidance of $0.70–$0.76 and FY 2026 EPS of $2.95–$3.05 are roughly around consensus but leave room for variance, which can limit upside if execution slips. Read More.
• Neutral Sentiment: Analyst positioning remains constructive—Multiple buy/overweight ratings and a median 12-month target near $98 point to continued analyst confidence, which can support the stock if results remain steady. Read More.
• Negative Sentiment: Insider selling and potential profit-taking—Recent notable insider sales and the large post-earnings run-up increase the risk of near-term selling pressure. Read More.
• Negative Sentiment: Mixed datapoints and market reaction—Although headlines emphasized a beat, some outlets highlighted differing EPS metrics and the stock’s reversal from its post-earnings pop, suggesting investors are parsing nuances rather than celebrating a clear clean beat. Read More.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.